William D. Figg
National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name William D. Figg as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:48 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT03478904 · Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate CancerNational Cancer Institute (NCI) · terminated · Prostate Cancer · principal investigator
- Ph1NCT03436745 · The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy FemalesNational Cancer Institute (NCI) · terminated · Prostatic Neoplasms · principal investigator
- N/ANCT02810405 · Collection of Tissue Blocks or Slides From Patients With CancerNational Cancer Institute (NCI) · completed · Tumor, Carcinogens, Neoplasm, Benign · principal investigator
- N/ANCT02706652 · Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer PatientsNational Cancer Institute (NCI) · terminated · Cancer · principal investigator
- N/ANCT02154022 · Collection of Pharmacokinetic Samples From People With Unanticipated Response, Significant Toxicity or Concern of Future ToxicityNational Cancer Institute (NCI) · enrolling by invitation · Cancer, Solid Tumors, Neoplasm · principal investigator
- N/ANCT01441089 · Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic AnalysisNational Cancer Institute (NCI) · recruiting · Prostate Cancer, Breast Cancer, Lung Cancer · principal investigator
- N/ANCT00923221 · Collection of Blood From Patients With Prostate CancerNational Cancer Institute (NCI) · recruiting · Cancer Of Prostate, Prostate Cancer, Prostatic Neoplasms · principal investigator
- N/ANCT00900185 · Study of a Polymorphism in Patients With Prostate CancerNational Cancer Institute (NCI) · completed · Prostate Cancer · study chair
- N/ANCT00880503 · Collection of Tissue Samples for Study of Multidrug ResistanceNational Cancer Institute (NCI) · completed · Breast Carcinoma, Breast Cancer, Medullary Thyroid Carcinoma · principal investigator
- Ph2NCT00019695 · Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate CancerNational Cancer Institute (NCI) · terminated · Stage IV Prostate Cancer, Bone Metastases, Adenocarcinoma of the Prostate · study chair
- N/ANCT00339664 · Analyses of Human Samples Collected in Clinical TrialsNational Cancer Institute (NCI) · completed · Leukemia, Myeloid, Neoplasm Metastasis, Leukemia, Lymphoid · principal investigator
- N/ANCT00341939 · Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics DataNational Cancer Institute (NCI) · completed · Prostate Cancer, Breast Cancer, Cutaneous T-Cell Lymphoma · principal investigator
- Ph1NCT00095914 · Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid TumorsNational Institutes of Health Clinical Center (CC) · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- N/ANCT00040729 · Genetic Study of Patients Previously Treated With Flavopiridol on Clinical Trial NCI-97-C-0171CNational Cancer Institute (NCI) · completed · Unspecified Adult Solid Tumor, Protocol Specific · study chair
- N/ANCT00026663 · Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug ResistanceNational Cancer Institute (NCI) · completed · Renal Cell Carcinoma, Lung Carcinoma, Cervical Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Biospecimen Processing and BiorepositoryZICSC006536 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 2009 to 2025 · $2,211,062 awarded in 2025Same name and institution; not confirmed by an ID
- Clinical PharmacogeneticsZIABC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $1,028,401 awarded in 2025Same name and institution; not confirmed by an ID
- Clinical Pharmacology and Drug-Drug Interactions in HIV-Associated MalignancyZIABC011996 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 to 2025 · $102,841 awarded in 2025Same name and institution; not confirmed by an ID
- Development of Anticancer AgentsZIASC006538 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 2009 to 2025 · $587,204 awarded in 2025Same name and institution; not confirmed by an ID
- Drug Development for Prostate CancerZIABC010547 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $782,938 awarded in 2025Same name and institution; not confirmed by an ID
- Genetics and Molecular Mechanisms of Prostate CancerZIABC010453 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2025 · $587,204 awarded in 2025Same name and institution; not confirmed by an ID
- Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZICSC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 2009 to 2025 · $1,799,703 awarded in 2025Same name and institution; not confirmed by an ID
- COVID-19 Genetics and Drug DevelopmentZIABC011974 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2020 to 2021 · $75,915 awarded in 2021Same name and institution; not confirmed by an ID
- Pharmacokinetic and Pharmacodynamic Modeling of Anticancer AgentsZICBC010548 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2018 · $344,144 awarded in 2018Same name and institution; not confirmed by an ID
- Clinical PharmacogeneticsZ01BC010627 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2004 to 2008 · $582,605 awarded in 2008Same name and institution; not confirmed by an ID
- Development of Angiogenesis InhibitorsZ01SC006538 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $291,303 awarded in 2008Same name and institution; not confirmed by an ID
- Development of Drugs That Target Prostate CancerZ01BC010547 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2003 to 2008 · $291,303 awarded in 2008Same name and institution; not confirmed by an ID
- Identify SNPs and Polymorphisms Involved in the Development of Prostate CancerZ01BC010453 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2002 to 2008 · $582,605 awarded in 2008Same name and institution; not confirmed by an ID
- Pharmacokinetic and Pharmacodynamic Modeling of Anticancer AgentsZ01BC010548 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2003 to 2008 · $582,605 awarded in 2008Same name and institution; not confirmed by an ID
- Sample Processing and Analytical Methods Development for New Anticancer AgentsZ01SC006536 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $436,954 awarded in 2008Same name and institution; not confirmed by an ID
- Using Clinical Pharmacology Principles to Develop New Anticancer TherapiesZ01SC006537 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2008 · $145,651 awarded in 2008Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:48 UTC. The ranking covers the 200 most relevant of 236 PubMed records, and a shared surname and initials can bring in a namesake. All 236 on PubMed
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.J Hepatol · 2017662 citationsRCR 22.0
- 605 citationsRCR 17.1
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.J Clin Oncol · 2009602 citationsRCR 12.9
- Selumetinib in Children with Inoperable Plexiform Neurofibromas.N Engl J Med · 2020570 citationsRCR 26.0
- Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clin Cancer Res · 2002480 citationsRCR 9.4
- 409 citationsRCR 10.0
- Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.Proc Natl Acad Sci U S A · 2000379 citationsRCR 8.0
- Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).Clin Cancer Res · 2005373 citationsRCR 8.8
- Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.J Clin Oncol · 2000363 citationsRCR 8.9
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.J Clin Oncol · 1998363 citationsRCR 7.2